News | February 06, 2015

CMS has determined that the evidence is sufficient to add screening as an additional preventive service benefit under the Medicare program under certain criteria

CMS Issues Final National Coverage Determination on Screening for Lung Cancer with LDCT

The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to add a lung cancer screening, counseling and shared decision making visit, and for appropriate beneficiaries, annual screening for lung cancer with low dose computed tomography (LDCT), as an additional preventive service benefit under the Medicare program only if all of the following criteria are met:

Beneficiary eligibility criteria: 

  • Age 55 – 77 years;
  • Asymptomatic (no signs or symptoms of lung cancer);
  • Tobacco smoking history of at least 30 pack-years (one pack-year = smoking one pack per day for one year; 1 pack = 20 cigarettes);
  • Current smoker or one who has quit smoking within the last 15 years; and
  • Receives a written order for LDCT lung cancer screening that meets the following criteria:
    • For the initial LDCT lung cancer screening service:  a beneficiary must receive a written order for LDCT lung cancer screening during a lung cancer screening counseling and shared decision making visit, furnished by a physician (as defined in Section 1861(r)(1) of the Social Security Act) or qualified non-physician practitioner (meaning a physician assistant, nurse practitioner, or clinical nurse specialist as defined in §1861(aa)(5) of the Social Security Act).  A lung cancer screening counseling and shared decision making visit includes the following elements (and is appropriately documented in the beneficiary’s medical records):
      • Determination of beneficiary eligibility including age, absence of signs or symptoms of lung cancer, a specific calculation of cigarette smoking pack-years; and if a former smoker, the number of years since quitting;
      • Shared decision making, including the use of one or more decision aids, to include benefits and harms of screening, follow-up diagnostic testing, over-diagnosis, false positive rate, and total radiation exposure;
      • Counseling on the importance of adherence to annual lung cancer LDCT screening, impact of comorbidities and ability or willingness to undergo diagnosis and treatment; 
      • Counseling on the importance of maintaining cigarette smoking abstinence if former smoker; or the importance of smoking cessation if current smoker and, if appropriate, furnishing of information about tobacco cessation interventions; and
      • If appropriate, the furnishing of a written order for lung cancer screening with LDCT.  
    • For subsequent LDCT lung cancer screenings:  the beneficiary must receive a written order for LDCT lung cancer screening, which may be furnished during any appropriate visit with a physician (as defined in Section 1861(r)(1) of the Social Security Act) or qualified non-physician practitioner (meaning a physician assistant, nurse practitioner, or clinical nurse specialist as defined in Section 1861(aa)(5) of the Social Security Act).  If a physician or qualified non-physician practitioner elects to provide a lung cancer screening counseling and shared decision making visit for subsequent lung cancer screenings with LDCT, the visit must meet the criteria described above for a counseling and shared decision making visit.
    • Written orders for both initial and subsequent LDCT lung cancer screenings must contain the following information, which must also be appropriately documented in the beneficiary’s medical records:
      • Beneficiary date of birth;
      • Actual pack - year smoking history (number);
      • Current smoking status, and for former smokers, the number of years since quitting smoking;
      • Statement that the beneficiary is asymptomatic (no signs or symptoms of lung cancer); and
      • National Provider Identifier (NPI) of the ordering practitioner. 

Reading radiologist eligibility criteria: 

  • Board certification or board eligibility with the American Board of Radiology or equivalent organization;
  • Documented training in diagnostic radiology and radiation safety;
  • Involvement in the supervision and interpretation of at least 300 chest computed tomography acquisitions in the past 3 years;
  • Documented participation in continuing medical education in accordance with current American College of Radiology standards; and
  • Furnish lung cancer screening with LDCT in a radiology imaging facility that meets the radiology imaging facility eligibility criteria below.   

Radiology imaging facility eligibility criteria: 

  • Performs LDCT with volumetric CT dose index (CTDIvol) of ? 3.0 mGy (milligray) for standard size patients (defined to be 5’ 7” and approximately 155 pounds) with appropriate reductions in CTDIvol for smaller patients and appropriate increases in CTDIvol for larger patients;
  • Utilizes a standardized lung nodule identification, classification and reporting system;
  • Makes available smoking cessation interventions for current smokers; and
  • Collects and submits data to a CMS-approved registry for each LDCT lung cancer screening performed.  The data collected and submitted to a CMS-approved registry must include, at minimum, all of the following elements:
Data Type Minimum Required Data Elements

Facility

Identifier

Radiologist (reading)

National Provider Identifier (NPI)

Patient

Identifier

Ordering Practitioner

National Provider Identifier (NPI)

CT scanner

Manufacturer, Model.

Indication

Lung cancer LDCT screening – absence of signs or symptoms of lung cancer

System

Lung nodule identification, classification and reporting system

Smoking history

Current status (current, former, never).
If former smoker, years since quitting.
Pack-years as reported by the ordering practitioner.
For current smokers, smoking cessation interventions available.

Effective radiation dose

CT Dose Index (CTDIvol).

Screening

Screen date   
Initial screen or subsequent screen

All CMS-approved registries must have the capacity and capability to collect data from any Medicare-eligible imaging facility/department that furnishes lung cancer screening with LDCT, with a catchment area that includes all 50 States, United States Territories, and the District of Columbia.  CMS will evaluate each entity interested in participating as a CMS-approved registry to determine if they are capable of meeting the registry and data collection requirements outlined in this national coverage determination, including:

  1. Establishment of a steering committee and a governance board for oversight of the registry;
  2. Registry management plan, including identification of key personnel;
  3. Operational plan and framework that describes mechanisms for collection and submission of data from imaging facilities to the registry;
  4. Registry catchment area;
  5. Mechanisms for the submission of registry data to CMS electronically;
  6. Mechanisms to collect information (e.g.; HICN) in order to permit linkage of registry data with external databases (e.g. Medicare claims data sets); 
  7. Description of data management and data quality review methods, including validation;
  8. Use of CMS-approved standardized data dictionary;
  9. Mechanisms for submitting a list of facilities participating in the registry to CMS; and
  10. Quality assurance plan. 

To apply to function as a CMS-approved registry, interested entities must submit a letter of interest along with detailed supporting information about how the interested entity is able to meet the requirements outlined in this national coverage determination to the following address or via email to [email protected].  

For more information:http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo…


Related Content

News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Radiation Therapy

July 3, 2024 — Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support ...

Time July 03, 2024
arrow
News | Artificial Intelligence

June 27, 2024 — Thirona, a Netherlands-based global company providing high-precision advanced lung image analysis with ...

Time June 27, 2024
arrow
Subscribe Now